An $86,880 grant from the National Science Foundation will support the development of computer simulations that aim to improve scientists’ understanding of the neuromuscular junction (NMJ) — the site where nerve cells connect with muscles. The results may help researchers find treatments for Lambert-Eaton myasthenic syndrome (LEMS)…
Health Canada has approved Ruzurgi (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in individuals ages 6 or older. In Canada, the oral medication will be commercialized by Médunik Canada, per an agreement with Jacobus Pharmaceuticals, the original developer of Ruzurgi. “We are proud…
Autoantibodies against a protein called GRP78 may lead to paraneoplastic cerebellar degeneration (PCD) in people with Lambert-Eaton myasthenic syndrome (LEMS), a study suggests. The study, “GRP78 antibodies are associated with blood-brain barrier breakdown in paraneoplastic cerebellar degeneration in Lambert‐Eaton myasthenic syndrome,” was published in the…
A case of Lambert-Eaton myasthenic syndrome (LEMS) that occurred secondary to lung cancer highlights the need for comprehensive antibody testing when doctors suspect that the immune system might be attacking the nervous system. The case was described in Thoracic Cancer, in the paper, “Anti-SOX1 antibody-positive paraneoplastic neurological syndrome…
A recent case report of a man diagnosed with simultaneous Lambert-Eaton myasthenic syndrome (LEMS) and limbic encephalitis (LE) highlights the need for thorough screening of patients, especially those with unusual symptoms. The case report, titled “Paraneoplastic Lambert–Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of…
Get regular updates to your inbox.